Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers

BACKGROUND. Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Carlo-Stella, Carmelo, Ricci, Francesca, Dalto, Serena, Mazza, Rita, Malagola, Michele, Patriarca, Francesca, Viviani, Simonetta, Russo, Domenico, Giordano, Laura, Castagna, Luca, Corradini, Paolo, Santoro, Armando
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2015
Aiheet:
Lymphoma
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4350807/
https://ncbi.nlm.nih.gov/pubmed/25669663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0420
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia